特利加压素治疗肝肾综合征-急性肾损伤患者中的心动过缓及其他心律失常:三项北美III期临床研究的汇总分析
该汇总分析整合OT-0401、REVERSE、CONFIRM三项北美III期随机安慰剂对照研究,评估特利加压素治疗肝肾综合征-急性肾损伤相关心脏不良事件。特利加压素组心动过缓发生率6.3%(22/349)高于安慰剂组0.8%(2/249),其他心律失常不良事件两组相似(特利加压素7.4%[26/349] vs 安慰剂8.8%[22/249])。作者认为常规强化心脏监测以检出心律失常可能并非必要。
要点
- 特利加压素组心动过缓发生率6.3%(22/349),高于安慰剂组0.8%(2/249)。
- 特利加压素组心动过缓无严重事件,4.5%(1/22)需中断给药,9.1%(2/22)需减量,无因心动过缓停药。
- 其他心律失常不良事件发生率两组相似:特利加压素7.4%(26/349) vs 安慰剂8.8%(22/249)。
核心结论
- 汇总分析中,6%接受特利加压素治疗的患者观察到心动过缓,但罕需中断或减少剂量。
- 心律失常严重不良事件发生率低且两组相似。
- 作者认为特利加压素给药期间常规强化心脏监测以检出心律失常可能并非必要。
研究设计与样本
- 三项以北美为中心的III期随机安慰剂对照研究(OT-0401、REVERSE、CONFIRM)汇总为迄今最大的前瞻性数据库。
- 心脏不良事件由各试验研究者报告并回顾性分析。
主要发现
- 心动过缓是唯一在特利加压素组较安慰剂组更常报告的心脏不良事件:6.3%(22/349) vs 0.8%(2/249)。
- 特利加压素组心动过缓不良事件均非严重,4.5%(1/22)需中断给药,9.1%(2/22)需减量,无因心动过缓停药。
- 其他心律失常不良事件发生率两组相似:特利加压素7.4%(26/349) vs 安慰剂8.8%(22/249)。
- 心房颤动严重不良事件发生率低:特利加压素0.9%(3/349) vs 安慰剂1.6%(4/249)。
- 无尖端扭转型室速不良事件报告,两例患者报告QT间期延长。
临床怎么用
- 作者认为特利加压素给药期间常规强化心脏监测以检出心律失常可能并非必要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Terlipressin is the FDA-approved systemic vasoconstrictor therapy for hepatorenal syndrome-acute kidney injury (HRS-AKI)-a rapidly progressive renal failure occurring in patients with decompensated cirrhosis and ascites. Bradycardia, a known effect of terlipressin, as well as other arrhythmias, has previously been reported in terlipressin-treated patients. AIM: To assess terlipressin-related cardiac adverse events (AEs) in patients with HRS-AKI. METHODS: Three North American-centric Phase III, randomised, placebo-controlled studies (OT-0401, REVERSE, CONFIRM) were pooled in the largest-to-date prospective database. Cardiac AEs were reported by the investigators for each trial and retrospectively analysed. RESULTS: Bradycardia was the only cardiac AE reported more frequently in terlipressin-treated patients compared with placebo (6.3% [22/349] vs. 0.8% [2/249]). In the terlipressin group, no bradycardia AEs were serious, 4.5% (1/22) of patients required a dose interruption, 9.1% (2/22) required a dose reduction, and none discontinued treatment due to bradycardia. The incidences of other arrhythmia AEs were similar in both treatment groups (terlipressin: 7.4% [26/349]; placebo 8.8% [22/249]). The incidence of atrial fibrillation serious AEs (SAEs) was low (terlipressin: 0.9% [3/349]; placebo: 1.6% [4/249]). There were no AE reports of torsades de pointes, while a QT interval prolongation was reported in two patients. CONCLUSIONS: In a pooled analysis, bradycardia was observed in 6% of terlipressin-treated patients but rarely required a dose interruption or reduction. Arrhythmia SAE incidences were low and similar in both treatment groups. Routine intensive cardiac monitoring for the detection of arrhythmias may not be necessary during terlipressin administration. TRIAL REGISTRATION: OT-0401: NCT00089570, REVERSE: NCT01143246 and CONFIRM: NCT02770716.
引用
- Bajaj JS, Kwo P, Pappas SC, et al. Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies. Aliment Pharmacol Ther. 2025. PMID: 40704461. doi:10.1111/apt.70297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。